偏頭痛（Migraine）：グローバル医薬品市場予測及び分析（～2023）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 24
2.3 Upcoming Related Reports 24
3 Disease Overview 25
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 28
3.1.3 Prognosis 29
3.2 Symptoms 29
3.2.1 Premonitory Phase 30
3.2.2 Aura Phase 30
3.2.3 Headache Phase 31
3.2.4 Postdrome Phase 31
4 Epidemiology 32
4.1 Disease Background 32
4.2 Risk Factors and Comorbidities 33
4.2.1 Female sex and family history are interrelated risk factors of migraine 33
4.2.2 People with migraine also suffer from several comorbidities 34
4.3 Global Trends 35
4.3.1 US 36
4.3.2 5EU 37
4.3.3 Japan 38
4.4 Forecast methodology 39
4.4.1 Sources used 41
4.4.2 Sources not used 44
4.4.3 Forecast assumptions and methods 44
4.5 Epidemiological Forecast for Migraine (2013-2023) 49
4.5.1 Total Prevalent Cases of Migraine 49
4.5.2 Age-Specific Total Prevalent Cases of Migraine 50
4.5.3 Sex-Specific Total Prevalent Cases of Migraine 52
4.5.4 Age-Standardized Total Prevalence of Migraine 54
4.5.5 Total Prevalent Cases of Migraine with Aura and Migraine without Aura 55
4.6 Discussion 57
4.6.1 Conclusions on Epidemiological Trends 57
4.6.2 Limitations of the Analysis 58
4.6.3 Strengths of the Analysis 59
5 Disease Management 60
5.1 Treatment Overview 60
5.1.1 Acute Migraine Treatment 63
5.1.2 Preventive Migraine Treatment 64
5.2 US 65
5.2.1 Diagnosis 65
5.2.2 Clinical Practice 65
5.3 France 66
5.3.1 Diagnosis 66
5.3.2 Clinical Practice 66
5.4 Germany 67
5.4.1 Diagnosis 67
5.4.2 Clinical Practice 68
5.5 Italy 69
5.5.1 Diagnosis 69
5.5.2 Clinical Practice 69
5.6 Spain 70
5.6.1 Diagnosis 70
5.6.2 Clinical Practice 70
5.7 UK 71
5.7.1 Diagnosis 71
5.7.2 Clinical Practice 72
5.8 Japan 73
5.8.1 Diagnosis 73
5.8.2 Clinical Practice 73
6 Competitive Assessment 74
6.1 Overview 74
6.2 Strategic Competitor Assessment 75
6.3 Product Profiles- Major Brands 76
6.3.1 Triptans 76
6.3.2 Imitrex (sumatriptan) 78
6.3.3 Zomig (zolmitriptan) 81
6.3.4 Amerge (naratriptan) 84
6.3.5 Maxalt (rizatriptan) 86
6.3.6 Axert (almotriptan) 89
6.3.7 Frova (frovatriptan) 91
6.3.8 Relpax (eletriptan) 93
6.3.9 Sumavel DosePro (sumatriptan) 96
6.3.10 Ergot Alkaloids 99
6.3.11 Beta Blockers 105
6.3.12 Anti-Epileptics 108
6.3.13 Antidepressants 112
6.3.14 Calcium Channel Antagonists 115
6.3.15 Botox (onabotulinum toxin A) 118
7 Opportunity and Unmet Need 122
7.1 Overview 122
7.1.1 A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders 123
7.1.2 Lack of Acute Therapies for Patients Unresponsive to Triptan Medication 123
7.1.3 Lack of Diagnostic Tools Causes Misdiagnosis 124
7.1.4 Physician Education 124
7.1.5 Effective and Well-Tolerated Prophylactic Therapies 125
7.2 Unmet Needs Gap Analysis 125
7.2.1 Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication 127
7.2.2 Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies 127
7.2.3 Physician Education 128
7.2.4 Diagnostic Tools 128
8 Pipeline Assessment 129
8.1 Overview 129
8.2 Clinical Trial Mapping 130
8.2.1 Clinical Trials by Country 130
8.3 Clinical Trials by Phase and Trial status 131
8.4 Promising drugs in clinical development 132
8.4.1 Zecuity 134
8.4.2 Levadex 139
8.4.3 RHB-103 144
8.4.4 AVP-825 148
8.4.5 Lasmiditan 154
8.4.6 MK-1602 160
8.4.7 SUD-001 165
8.4.8 RT-001 169
8.4.9 NXN-188 171
9 Current and Future Players 174
9.1 Overview 174
9.2 Trends in Corporate Strategy 177
9.3 Company Profiles 178
9.3.1 GlaxoSmithKline 178
9.3.2 AstraZeneca 181
9.3.3 Merck 183
9.3.4 Vernalis 185
9.3.5 Almirall 186
9.3.6 Pfizer 187
9.3.7 Zogenix 188
9.3.8 NuPathe 189
9.3.9 Allergan 191
9.3.10 RedHill Biopharma 192
9.3.11 OptiNose 193
9.3.12 CoLucid Pharmaceuticals 195
9.3.13 SUDA 196
9.3.14 Revance Therapeutics 197
9.3.15 NeurAxon 198
10 Market Outlook 200
10.1 Global Markets 200
10.1.1 Forecast 200
10.1.2 Drivers and Barriers – Global Issues 204
10.2 US 204
10.2.1 Forecast 204
10.2.2 Key Events 209
10.2.3 Drivers and Barriers 209
10.3 France 211
10.3.1 Forecast 211
10.3.2 Key Events 215
10.3.3 Driver and Barriers 215
10.4 Germany 216
10.4.1 Forecast 216
10.4.2 Key Events 220
10.4.3 Driver and Barriers 220
10.5 Italy 221
10.5.1 Forecast 221
10.5.2 Key Events 225
10.5.3 Driver and Barriers 225
10.6 Spain 227
10.6.1 Forecast 227
10.6.2 Key Events 231
10.6.3 Driver and Barriers 231
10.7 United Kingdom 232
10.7.1 Forecast 232
10.7.2 Key Events 236
10.7.3 Driver and Barriers 236
10.8 Japan 238
10.8.1 Forecast 238
10.8.2 Key Events 242
10.8.3 Driver and Barriers 242
11 Appendix 244
11.1 Bibliography 244
11.2 Abbreviations 257
11.3 Methodology 260
11.4 Forecasting Methodology 260
11.4.1 Diagnosed Migraine Patients 260
11.4.2 Percent Drug-treated Patients 260
11.4.3 Drugs Included in Each Therapeutic Class 261
11.4.4 Launch and Patent Expiry Dates 262
11.4.5 General Pricing Assumptions 263
11.4.6 Individual Drug Assumptions 264
11.4.7 Generic Erosion 271
11.4.8 Pricing of Pipeline agents 271
11.5 Physicians and Specialists Included in this Study 273
11.6 Survey of Prescribing Physicians 274
11.7 About the Authors 275
11.7.1 Author 275
11.7.2 Reviewer 275
11.7.3 Epidemiologist 276
11.7.4 Global Head of Healthcare 276
11.8 About GlobalData 277
11.9 Disclaimer 277